vs
HERITAGE COMMERCE CORP（HTBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
HERITAGE COMMERCE CORP的季度营收约是REGENXBIO Inc.的1.8倍（$53.6M vs $30.3M），HERITAGE COMMERCE CORP净利率更高（28.2% vs -221.3%，领先249.5%），REGENXBIO Inc.同比增速更快（43.0% vs 15.6%），HERITAGE COMMERCE CORP自由现金流更多（$61.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 12.8%）
本文介绍的企业主体信息与内容描述不符，描述内容实际为美国商会，该商会成立于1912年4月23日，是美国规模最大的游说类商业协会 advocacy 团体，成立之初得益于时任总统威廉·霍华德·塔夫脱与劳工商务部长查尔斯·内格尔推动，旨在代表工商界发声。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
HTBK vs RGNX — 直观对比
营收规模更大
HTBK
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出27.4%
15.6%
净利率更高
HTBK
高出249.5%
-221.3%
自由现金流更多
HTBK
多$114.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
12.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $30.3M |
| 净利润 | $15.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 41.0% | -190.0% |
| 净利率 | 28.2% | -221.3% |
| 营收同比 | 15.6% | 43.0% |
| 净利润同比 | 42.3% | -31.2% |
| 每股收益（稀释后） | $0.25 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBKRGNX
| Q4 25 | $53.6M | $30.3M | ||
| Q3 25 | $50.0M | $29.7M | ||
| Q2 25 | $47.8M | $21.4M | ||
| Q1 25 | $46.1M | $89.0M | ||
| Q4 24 | $46.4M | $21.2M | ||
| Q3 24 | $42.2M | $24.2M | ||
| Q2 24 | $41.7M | $22.3M | ||
| Q1 24 | $42.1M | $15.6M |
净利润HTBKRGNX
| Q4 25 | $15.1M | $-67.1M | ||
| Q3 25 | $14.7M | $-61.9M | ||
| Q2 25 | $6.4M | $-70.9M | ||
| Q1 25 | $11.6M | $6.1M | ||
| Q4 24 | $10.6M | $-51.2M | ||
| Q3 24 | $10.5M | $-59.6M | ||
| Q2 24 | $9.2M | $-53.0M | ||
| Q1 24 | $10.2M | $-63.3M |
毛利率HTBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率HTBKRGNX
| Q4 25 | 41.0% | -190.0% | ||
| Q3 25 | 41.1% | -176.3% | ||
| Q2 25 | 18.7% | -296.3% | ||
| Q1 25 | 35.4% | 13.6% | ||
| Q4 24 | 31.8% | -242.1% | ||
| Q3 24 | 34.3% | -256.6% | ||
| Q2 24 | 31.3% | -251.3% | ||
| Q1 24 | 34.2% | -408.8% |
净利率HTBKRGNX
| Q4 25 | 28.2% | -221.3% | ||
| Q3 25 | 29.4% | -208.3% | ||
| Q2 25 | 13.4% | -331.8% | ||
| Q1 25 | 25.2% | 6.8% | ||
| Q4 24 | 22.9% | -241.3% | ||
| Q3 24 | 24.9% | -246.3% | ||
| Q2 24 | 22.1% | -237.7% | ||
| Q1 24 | 24.1% | -405.4% |
每股收益（稀释后）HTBKRGNX
| Q4 25 | $0.25 | $-1.30 | ||
| Q3 25 | $0.24 | $-1.20 | ||
| Q2 25 | $0.10 | $-1.38 | ||
| Q1 25 | $0.19 | $0.12 | ||
| Q4 24 | $0.17 | $-0.99 | ||
| Q3 24 | $0.17 | $-1.17 | ||
| Q2 24 | $0.15 | $-1.05 | ||
| Q1 24 | $0.17 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $708.6M | $102.7M |
| 总资产 | $5.8B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HTBKRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益HTBKRGNX
| Q4 25 | $708.6M | $102.7M | ||
| Q3 25 | $700.0M | $161.5M | ||
| Q2 25 | $694.7M | $213.7M | ||
| Q1 25 | $696.2M | $274.2M | ||
| Q4 24 | $689.7M | $259.7M | ||
| Q3 24 | $685.4M | $301.4M | ||
| Q2 24 | $679.2M | $348.3M | ||
| Q1 24 | $676.3M | $390.7M |
总资产HTBKRGNX
| Q4 25 | $5.8B | $453.0M | ||
| Q3 25 | $5.6B | $525.2M | ||
| Q2 25 | $5.5B | $581.0M | ||
| Q1 25 | $5.5B | $490.9M | ||
| Q4 24 | $5.6B | $466.0M | ||
| Q3 24 | $5.6B | $519.1M | ||
| Q2 24 | $5.3B | $569.4M | ||
| Q1 24 | $5.3B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $61.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 114.3% | -174.0% |
| 资本支出强度资本支出/营收 | 0.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.08× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流HTBKRGNX
| Q4 25 | $61.7M | $-52.3M | ||
| Q3 25 | $18.9M | $-56.0M | ||
| Q2 25 | $8.0M | $-49.3M | ||
| Q1 25 | $14.8M | $33.6M | ||
| Q4 24 | $39.0M | $-31.6M | ||
| Q3 24 | $5.3M | $-40.5M | ||
| Q2 24 | $10.5M | $-45.5M | ||
| Q1 24 | $7.3M | $-55.5M |
自由现金流HTBKRGNX
| Q4 25 | $61.3M | $-52.8M | ||
| Q3 25 | $18.8M | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $37.3M | $-32.7M | ||
| Q3 24 | $4.9M | $-40.9M | ||
| Q2 24 | $9.9M | $-46.0M | ||
| Q1 24 | $6.9M | $-56.0M |
自由现金流率HTBKRGNX
| Q4 25 | 114.3% | -174.0% | ||
| Q3 25 | 37.7% | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | 80.5% | -154.2% | ||
| Q3 24 | 11.6% | -168.9% | ||
| Q2 24 | 23.6% | -206.2% | ||
| Q1 24 | 16.4% | -358.5% |
资本支出强度HTBKRGNX
| Q4 25 | 0.7% | 1.7% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 3.5% | 5.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 1.6% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率HTBKRGNX
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.28× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.28× | 5.53× | ||
| Q4 24 | 3.67× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 0.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTBK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
